Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPSE | Q9Y251 | 7/20 | 0.34 |
| ▸ | FGF1 | P05230 | 6/20 | 0.34 |
| ▸ | FGF2 | P09038 | 6/20 | 0.34 |
| ▸ | VEGFA | P15692 | 4/20 | 0.34 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 4/20 | 0.33 |
| ▸ | CA2 | P00918 | 4/20 | 0.33 |
| ▸ | CA9 | Q16790 | 4/20 | 0.33 |
| ▸ | SELP | P16109 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13901508 | 0.91 | HPSE (0.38) | HPSEFGF1FGF2VEGFACA1 | |
| SCHEMBL12480784 | 0.91 | HPSE (0.38) | HPSEFGF1FGF2VEGFACA1 | |
| SCHEMBL13249004 | 0.87 | HPSE (0.38) | HPSEFGF1FGF2VEGFATNF | |
| SCHEMBL13224917 | 0.85 | FGF1 (0.40) | HPSEFGF1FGF2VEGFACA1 | |
| SCHEMBL4158124 | 0.85 | CA2 (0.36) | CA1CA2CA9 | |
| SCHEMBL13697499 | 0.85 | CA2 (0.36) | CA1CA2CA9 | |
| SCHEMBL13697309 | 0.85 | CA2 (0.36) | CA1CA2CA9 | |
| SCHEMBL14765411 | 0.85 | CA2 (0.36) | CA1CA2CA9 | |
| SCHEMBL2533441 | 0.84 | CA2 (0.38) | CA1CA2CA9 | |
| SCHEMBL13224987 | 0.84 | CA2 (0.38) | CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100202971-A1 | COMPOUND HAVING TUMOR-RESIDENT PROPERTY | OHTA KEISUKE | 2010-08-12 | — | — | US | disclosed |
| WO-2010082634-A1 | COMPOUND RETAINED IN TUMOR | 東洋水産株式会社 (JP) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100202971-A1 | COMPOUND HAVING TUMOR-RESIDENT PROPERTY | HRH3, HRH4, HNRNPH3 | HPSE 1420/4885FGF1 3729/4885FGF2 4086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.